GlassScriptPhysician profile
Gavin Michael Kolodge
NPI 1407210537
$9,223.13
in general payments reported to CMS, 2019-2025
29 companies · $850 in 2025
The $850 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,030 · 2021: $2,999 · 2022: $1,879 · 2023: $1,380 · 2024: $1,084 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,992 · Travel and Lodging: $288 · Education: $35.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,991.63 |
| Travel and Lodging | $288.18 |
| Education | $35.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,719.16 | 2020-2025 | Wavewriter Alpha Prime 16, Intracept |
| Abbott Laboratories | $1,328.46 | 2021-2025 | Proclaim, Eterna, Octrode |
| Medtronic, INC. | $1,275.33 | 2021-2025 | Inceptiv |
| Curonix LLC | $521.88 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nevro Corp. | $507.50 | 2022-2024 | Senza |
| Spr Therapeutics, INC | $495.33 | 2020-2025 | Sprint Pns System |
| Pacira Pharmaceuticals Incorporated | $352.18 | 2021-2025 | Iovera, Exparel, Zilretta |
| Merz Pharmaceuticals, LLC | $275.10 | 2021-2022 | |
| Stimwave Technologies Incorporated | $247.44 | 2020-2022 | |
| Elevate Surgical Co | $160.03 | 2023-2024 | |
| Globus Medical, INC. | $155.92 | 2025 | Senza, Vyrsa V1 |
| Painteq LLC | $152.32 | 2022-2024 | Painteq |
| Breg, INC | $127.80 | 2022 | |
| Avanos Medical | $112.86 | 2021 | |
| Integra Lifesciences Corporation | $109.29 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $100.14 | 2023-2025 | Hymovis, Triluron |
| Linvatec Corporation | $97.27 | 2023 | Biobrace 23mm |
| Electronic Waveform Lab, INC. | $75.53 | 2022 | |
| Saluda Medical Americas, INC. | $58.50 | 2023-2025 | Evoke, Evoke Scs |
| Collegium Pharmaceutical, INC. | $53.05 | 2024-2025 | Belbuca |
| Bioventus LLC | $48.08 | 2022-2025 | Exogen Ultrasound Bone Healing System, Supartz Fx Sodium Hyaluronate |
| Lilly USA, LLC | $44.95 | 2022 | |
| Acera Surgical, INC. | $42.39 | 2024-2025 | Restrata Wound Matrix |
| Vertos Medical, INC. | $36.77 | 2023 | Mild Device Kit |
| Stryker Corporation | $33.67 | 2021 | |
| Nalu Medical, INC. | $32.24 | 2024 | Nalu Neurostimulation System |
| Si-Bone, INC. | $24.66 | 2023 | |
| Smith+Nephew, INC. | $17.78 | 2024 | Katalyst Bipolar Radial Head System |
| Kowa Pharmaceuticals America, INC. | $17.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gavin Kolodge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.